Germline BRCA1 and BRCA2 Deleterious Mutations and Variants of Unknown Clinical Significance Associated With Breast/Ovarian Cancer: A Report From North India

Cancer Management and Research - New Zealand
doi 10.2147/cmar.s186563
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Informa UK Limited

Related search

Management of Breast Cancer Risk in Women With Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations

Annals of Surgical Oncology
OncologySurgery
2017English

Novel Germline Mutations and Unclassified Variants of BRCA1 and BRCA2 Genes in Chinese Women With Familial Breast/Ovarian Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

BRCA1 and BRCA2 Mutations and Clinical Interpretation in 398 Ovarian Cancer Patients: Comparison With Breast Cancer Variants in a Similar Population

Human Genomics
Molecular MedicineDrug DiscoveryGeneticsMolecular Biology
2018English

BRCA1 and BRCA2 Mutations in Danish Families With Hereditary Breast and/or Ovarian Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2008English

Intron Variants of the P53 Gene Are Associated With Increased Risk for Ovarian Cancer but Not in Carriers of BRCA1 or BRCA2 Germline Mutations

British Journal of Cancer
Cancer ResearchOncology
1999English

Hereditary Breast Cancer: Mutations Within BRCA1 and BRCA2 With Phenotypic Responses

2000English

Biallelic Deleterious BRCA1 Mutations in a Woman With Early-Onset Ovarian Cancer

Cancer Discovery
Oncology
2012English

Prevalence of BRCA1 and BRCA2 Mutations in Breast Cancer Patients From Brazil

Breast Cancer Research and Treatment
Cancer ResearchOncology
2006English

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women With Ovarian Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy